Introduction: Frontotemporal dementia (FTD) is a progressive disease for which no curative treatment is currently available. We aimed to determine whether transcranial direct current stimulation (tDCS) can modulate intracortical connectivity and improve cognition in symptomatic FTD patients and presymptomatic FTD subjects.
Methods: We performed a double-blind, randomized, sham-controlled trial with anodal tDCS or sham stimulation over the left prefrontal cortex in 70 participants (15 presymptomatic and 55 symptomatic FTD).
Results: We observed a significant increase of intracortical connectivity (short interval intracortical inhibition and facilitation) and improvement in clinical scores and behavioral disturbances in both symptomatic FTD patients and presymptomatic carriers after real tDCS but not after sham stimulation.
Discussion: A 2-weeks' treatment with anodal left prefrontal tDCS improves symptoms and restores intracortical inhibitory and excitatory circuits in both symptomatic FTD patients and presymptomatic carriers. tDCS might represent a promising future therapeutic and rehabilitative approach in patients with FTD.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7253155 | PMC |
| http://dx.doi.org/10.1002/trc2.12033 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The experience of "at-risk" status for familial frontotemporal dementia (fFTD) and its impact on reproductive decision-making: A qualitative study.
J Genet Couns
February 2025
Research Department of Clinical, Educational and Health Psychology, University College London, London, UK.
Familial frontotemporal dementia (fFTD) is an autosomal dominant heritable form of FTD, onsetting in mid-life, characterized by behavioral and personality changes. Children of an affected parent are at 50% risk of inheriting the relevant fFTD gene variant and developing FTD. Genetic testing means a growing group of people are aware of or considering learning their risk status.
View Article and Find Full Text PDFRivastigmine interferes with the pharmacological activity of hydromethylthionine on presynaptic proteins in the line 66 model of frontotemporal dementia.
Brain Res Bull
January 2025
School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, UK.
The negative interference of treatments between the acetylcholinesterase inhibitor rivastigmine and the tau aggregation inhibitor hydromethylthionine mesylate (HMTM) has been reported in Line 1 tau-transgenic mice, which overexpress a truncated species of tau protein that is found in the core of paired helical filaments in Alzheimer´s disease (AD). However, little is known about whether such interactions could affect synapses in mice overexpressing tau carrying pathogenic mutations. Here, we have used Line 66 (L66) mice which overexpress full-length human tau carrying the P301S mutation as a model in which tau accumulates in synapses.
View Article and Find Full Text PDFAnalysis of translatomic changes in the model of ALS reveals that motor neurons express muscle-associated genes in non-disease states.
Front Neurol
November 2024
Department of Anatomy, Cell Biology and Physiology, Indiana University School of Medicine, Indianapolis, IN, United States.
Article Synopsis
- ALS is a serious neurodegenerative disease that leads to progressive motor decline and paralysis, with an increase in identified gene mutations highlighting the need for new models to better understand the disease mechanisms.* -
- Researchers created a mouse model with the P497S mutation, which displayed motor symptoms similar to ALS, and by examining gene expression, they found motor neurons showed reduced survival and denervation of neuromuscular junctions at 12 months.* -
- Interestingly, key muscle-related genes were found to be downregulated in motor neurons of affected mice, suggesting these neurons may play a critical role in supporting muscle maintenance despite commonly being associated with muscle tissue.*
Expert opinions on pharmacological symptomatic treatment of behavioral symptoms in frontotemporal dementia: A survey of the Neuropsychiatric International Consortium on Frontotemporal Dementia (NIC-FTD).
Eur J Neurol
January 2025
Department of Clinical Sciences, Clinical Memory Research Unit, Faculty of Medicine, Lund University, Lund, Sweden.
Article Synopsis
- Behavioral variant frontotemporal dementia (bvFTD) leads to significant changes in personality and behavior, but there’s a lack of consensus on effective drug treatments despite high symptom burden for patients and caregivers.
- A survey of 48 experts in dementia treatment identified that disinhibition and compulsive behaviors are the primary symptoms targeted, with suggested medications including atypical antipsychotics and SSRIs.
- The findings indicate varied treatment approaches among professionals, highlighting the need for more research to develop consensus on effective pharmacological strategies for managing bvFTD symptoms.
The hyper-unstable Chr9p21 locus, harbouring the interferon gene cluster, oncogenes and is linked to multiple diseases. (GGGGCC)n expansions ( Exp) are associated with incompletely penetrant amyotrophic lateral sclerosis, frontotemporal dementia and autoimmune disorders. Exp patients display hyperactive cGAS-STING-linked interferon immune and DNA damage responses, but the source of immuno-stimulatory or damaged DNA is unknown.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!